vs
Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and National Vision Holdings, Inc. (EYE). Click either name above to swap in a different company.
Astrana Health, Inc. is the larger business by last-quarter revenue ($950.5M vs $487.3M, roughly 2.0× National Vision Holdings, Inc.). National Vision Holdings, Inc. runs the higher net margin — 0.7% vs 0.7%, a 0.0% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs 7.9%). National Vision Holdings, Inc. produced more free cash flow last quarter ($30.3M vs $-6.0M). Over the past eight quarters, Astrana Health, Inc.'s revenue compounded faster (53.3% CAGR vs 7.6%).
Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.
Vision Research is an international company that manufactures high-speed digital cameras based in Wayne, New Jersey. Their cameras are marketed under the Phantom brand, and are used in a broad variety of industries including: defense, industrial product development, manufacturing, automotive, scientific research, and entertainment. Vision Research is a business unit of the Materials Analysis Division of Ametek Inc., a global manufacturer of electronic instruments and electromechanical devices.
ASTH vs EYE — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $950.5M | $487.3M |
| Net Profit | $6.6M | $3.4M |
| Gross Margin | — | — |
| Operating Margin | 1.9% | 2.0% |
| Net Margin | 0.7% | 0.7% |
| Revenue YoY | 42.9% | 7.9% |
| Net Profit YoY | 184.4% | 139.8% |
| EPS (diluted) | $0.12 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $950.5M | — | ||
| Q3 25 | $956.0M | $487.3M | ||
| Q2 25 | $654.8M | $486.4M | ||
| Q1 25 | $620.4M | $510.3M | ||
| Q4 24 | $665.2M | $437.3M | ||
| Q3 24 | $478.7M | $451.5M | ||
| Q2 24 | $486.3M | $451.7M | ||
| Q1 24 | $404.4M | $482.8M |
| Q4 25 | $6.6M | — | ||
| Q3 25 | $373.0K | $3.4M | ||
| Q2 25 | $9.4M | $8.7M | ||
| Q1 25 | $6.7M | $14.2M | ||
| Q4 24 | $-7.8M | $-28.6M | ||
| Q3 24 | $16.1M | $-8.5M | ||
| Q2 24 | $19.2M | $-3.1M | ||
| Q1 24 | $14.8M | $11.7M |
| Q4 25 | 1.9% | — | ||
| Q3 25 | 2.0% | 2.0% | ||
| Q2 25 | 3.1% | 3.4% | ||
| Q1 25 | 3.3% | 5.1% | ||
| Q4 24 | 0.1% | -5.8% | ||
| Q3 24 | 5.9% | -2.0% | ||
| Q2 24 | 6.2% | 0.1% | ||
| Q1 24 | 7.5% | 4.9% |
| Q4 25 | 0.7% | — | ||
| Q3 25 | 0.0% | 0.7% | ||
| Q2 25 | 1.4% | 1.8% | ||
| Q1 25 | 1.1% | 2.8% | ||
| Q4 24 | -1.2% | -6.5% | ||
| Q3 24 | 3.4% | -1.9% | ||
| Q2 24 | 3.9% | -0.7% | ||
| Q1 24 | 3.7% | 2.4% |
| Q4 25 | $0.12 | — | ||
| Q3 25 | $0.01 | $0.04 | ||
| Q2 25 | $0.19 | $0.11 | ||
| Q1 25 | $0.14 | $0.18 | ||
| Q4 24 | $-0.14 | $-0.36 | ||
| Q3 24 | $0.33 | $-0.11 | ||
| Q2 24 | $0.40 | $-0.04 | ||
| Q1 24 | $0.31 | $0.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $429.5M | $56.0M |
| Total DebtLower is stronger | — | $236.5M |
| Stockholders' EquityBook value | $779.3M | $858.8M |
| Total Assets | $2.2B | $2.0B |
| Debt / EquityLower = less leverage | — | 0.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $429.5M | — | ||
| Q3 25 | $463.4M | $56.0M | ||
| Q2 25 | $342.1M | $48.5M | ||
| Q1 25 | $260.9M | $80.0M | ||
| Q4 24 | $290.8M | $73.9M | ||
| Q3 24 | $350.3M | $81.2M | ||
| Q2 24 | $327.7M | $179.5M | ||
| Q1 24 | $337.3M | $150.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | $236.5M | ||
| Q2 25 | — | $255.6M | ||
| Q1 25 | — | $244.7M | ||
| Q4 24 | — | $248.6M | ||
| Q3 24 | — | $252.8M | ||
| Q2 24 | — | $143.9M | ||
| Q1 24 | — | $448.6M |
| Q4 25 | $779.3M | — | ||
| Q3 25 | $775.5M | $858.8M | ||
| Q2 25 | $765.5M | $850.6M | ||
| Q1 25 | $745.4M | $836.2M | ||
| Q4 24 | $712.7M | $816.3M | ||
| Q3 24 | $704.6M | $840.0M | ||
| Q2 24 | $678.9M | $843.4M | ||
| Q1 24 | $653.5M | $841.3M |
| Q4 25 | $2.2B | — | ||
| Q3 25 | $2.2B | $2.0B | ||
| Q2 25 | $1.4B | $2.0B | ||
| Q1 25 | $1.3B | $2.0B | ||
| Q4 24 | $1.4B | $2.0B | ||
| Q3 24 | $1.3B | $2.0B | ||
| Q2 24 | $1.3B | $2.1B | ||
| Q1 24 | $1.2B | $2.2B |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.28× | ||
| Q2 25 | — | 0.30× | ||
| Q1 25 | — | 0.29× | ||
| Q4 24 | — | 0.30× | ||
| Q3 24 | — | 0.30× | ||
| Q2 24 | — | 0.17× | ||
| Q1 24 | — | 0.53× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.9M | $46.6M |
| Free Cash FlowOCF − Capex | $-6.0M | $30.3M |
| FCF MarginFCF / Revenue | -0.6% | 6.2% |
| Capex IntensityCapex / Revenue | 0.3% | 3.4% |
| Cash ConversionOCF / Net Profit | -0.44× | 13.83× |
| TTM Free Cash FlowTrailing 4 quarters | $104.5M | $83.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.9M | — | ||
| Q3 25 | $10.0M | $46.6M | ||
| Q2 25 | $90.9M | $54.3M | ||
| Q1 25 | $16.6M | $32.2M | ||
| Q4 24 | $-10.9M | $30.3M | ||
| Q3 24 | $34.0M | $27.9M | ||
| Q2 24 | $23.2M | $51.5M | ||
| Q1 24 | $6.0M | $24.0M |
| Q4 25 | $-6.0M | — | ||
| Q3 25 | $7.4M | $30.3M | ||
| Q2 25 | $89.5M | $42.4M | ||
| Q1 25 | $13.6M | $12.0M | ||
| Q4 24 | $-13.5M | $-1.7M | ||
| Q3 24 | $31.7M | $4.1M | ||
| Q2 24 | $20.4M | $31.9M | ||
| Q1 24 | $5.6M | $4.0M |
| Q4 25 | -0.6% | — | ||
| Q3 25 | 0.8% | 6.2% | ||
| Q2 25 | 13.7% | 8.7% | ||
| Q1 25 | 2.2% | 2.4% | ||
| Q4 24 | -2.0% | -0.4% | ||
| Q3 24 | 6.6% | 0.9% | ||
| Q2 24 | 4.2% | 7.1% | ||
| Q1 24 | 1.4% | 0.8% |
| Q4 25 | 0.3% | — | ||
| Q3 25 | 0.3% | 3.4% | ||
| Q2 25 | 0.2% | 2.4% | ||
| Q1 25 | 0.5% | 4.0% | ||
| Q4 24 | 0.4% | 7.3% | ||
| Q3 24 | 0.5% | 5.3% | ||
| Q2 24 | 0.6% | 4.3% | ||
| Q1 24 | 0.1% | 4.1% |
| Q4 25 | -0.44× | — | ||
| Q3 25 | 26.69× | 13.83× | ||
| Q2 25 | 9.65× | 6.22× | ||
| Q1 25 | 2.48× | 2.27× | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.11× | — | ||
| Q2 24 | 1.21× | — | ||
| Q1 24 | 0.40× | 2.05× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASTH
| Medicare | $542.4M | 57% |
| Commercial | $99.1M | 10% |
| Care Delivery | $92.1M | 10% |
| Care Enablement | $78.9M | 8% |
| Other Third Parties | $58.0M | 6% |
| Health Care Patient Service | $39.8M | 4% |
| Health Care Other | $25.5M | 3% |
| Other | $12.1M | 1% |
| Management Service | $10.3M | 1% |
EYE
Segment breakdown not available.
